Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 544
- Registration Number
- NCT00099892
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 362
- Registration Number
- NCT00099853
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
- Conditions
- First Posted Date
- 2004-12-21
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00099801
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
- Conditions
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 255
- Registration Number
- NCT00099749
- Locations
- ๐บ๐ธ
SIU School of Medicine, Springfield, Illinois, United States
๐บ๐ธSt. Barnabas Medical Center, Livingston, New Jersey, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 696
- Registration Number
- NCT00099736
Non-small Cell Lung Cancer Registry
- Conditions
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00099541
- Locations
- ๐บ๐ธ
Hembree Cancer Center-St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
๐บ๐ธGainesville Hematology Oncology Associates, Gainesville, Florida, United States
๐บ๐ธCenter for Cancer Care & Research, Lakeland, Florida, United States
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
- Conditions
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 747
- Registration Number
- NCT00099268
- Locations
- ๐บ๐ธ
Rush University Medical Center, Chicago, Illinois, United States
๐บ๐ธKeck School of Medicine, Division of Movement Disorders, Los Angeles, California, United States
๐บ๐ธReed Neurological Research Center, Los Angeles, California, United States
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
- Conditions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1040
- Registration Number
- NCT00099242
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
- Conditions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT00099229
- Locations
- ๐ท๐บ
Investigational Site, St. Petersburg, Russian Federation
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
- Conditions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 708
- Registration Number
- NCT00099216